J&J in talks to sell DePuy Synthes to Apollo for $20 billion

Johnson & Johnson (JNJ) announced that its experimental treatment JNJ-5120/PIPE-307 failed to meet the primary endpoint in a phase 2 trial for major depressive disorder. The company's dividend yield is 1.95% with a payout ratio of 50% and a 3-year growth rate of 4.9%. JNJ's stock is trading 37.8% above its intrinsic GF Value™ of $193.33, with a GF Score™ of 83/100. Insiders have sold $154.9 million in shares over the past year.

Johnson & Johnson (JNJ) is in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management for $20B. DePuy Synthes generated $9.3B in sales last year. The deal, if finalized, would be Apollo's largest healthcare investment. JNJ is also considering other separation options, including a spin-off, to maximize shareholder value.

Johnson & Johnson reported final results from the PAPILLON study, showing its amivantamab-based regimen achieved a median overall survival of 34.3 months in EGFR Ex20ins lung cancer patients, compared to 27.9 months for chemotherapy alone. The findings were presented at the IASLC 2026 World Conference on Lung Cancer. According to the company, the regimen demonstrated durability and value as a first-line treatment. The safety profile was consistent with earlier studies.

Johnson & Johnson (JNJ) stock rose 1.4% in pre-market trading after reports that Apollo Global Management is in talks to acquire its orthopedics division, DePuy Synthes, for around $20 billion. JNJ had planned to separate the division by October 2025. The company is also presenting at the Morgan Stanley Global Healthcare Conference and shared positive Phase 3 data for its lung cancer drug Rybrevant. The broader U.S. market is down, but JNJ's gain is driven by company-specific news.

Johnson & Johnson (JNJ) shares rose 1.3% to $268.96 in premarket trading on reports that Apollo Global (APO) is discussing a deal to buy its orthopedics unit, potentially valued at $20 billion. The unit generated $9.3 billion in 2025 revenue but faces lawsuits over hip replacement devices. A final agreement could be reached in weeks, according to Bloomberg.

Johnson & Johnson (JNJ) reported that its drug RYBREVANT, combined with chemotherapy, achieved a median overall survival of 34.3 months in patients with EGFR exon 20 insertion mutation-positive NSCLC, compared to 27.9 months for chemotherapy alone. The study showed a 43% reduction in risk of death when adjusting for crossover. RYBREVANT is already approved for multiple EGFR-mutated NSCLC settings. The company's stock closed at $265.58 on September 11, 2026.